RIS Rx

We are honored to welcome Tom Doyle to RIS Rx as a Senior Advisor. Tom brings decades of executive leadership across pharmaceutical distribution, biopharma services, and outsourced commercialization - and a deep belief in what RIS Rx is building in GTN Revenue Protection. Read the full story from our CEO, Gerard Rivera: https://lnkd.in/e3dufSGQ #RISRx #GTNRevenueProtection #Asembia

For years, pharma treated GTN as a back-office math problem for finance to handle. That worked—when it was all about reconciliation. But today, the real issue is the organizational split between finance and market access teams. RIS Rx Co-Founder and COO Stephen Hom highlights this issue: -- “The organizational split made sense when GTN was viewed as a backend financial reconciliation exercise. Affordability programs operate at the front of the patient journey where decisions have real-time financial consequences. 𝐖𝐡𝐞𝐧 𝐟𝐢𝐧𝐚𝐧𝐜𝐞 𝐭𝐞𝐚𝐦𝐬 𝐚𝐫𝐞 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐛𝐚𝐜𝐤𝐰𝐚𝐫𝐝𝐬, 𝐚𝐧𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐬𝐞𝐫𝐯𝐢𝐜𝐞𝐬 𝐭𝐞𝐚𝐦𝐬 𝐚𝐫𝐞 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫𝐰𝐚𝐫𝐝, 𝐥𝐞𝐚𝐤𝐚𝐠𝐞 𝐥𝐢𝐯𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐠𝐚𝐩 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝐭𝐡𝐞𝐦.” -- That gap is where billions are lost, where leakage starts—and where patients fall through. GTN isn’t just a look-back exercise with finance anymore. It’s a real-time operational challenge. ICYMI – be sure to register and watch our recent Xtalks webinar where Gerard Rivera and Stephen Hom dive deeper into this topic: https://lnkd.in/edTXMgDu

RIS Rx was founded by frontline pharmacists determined to make sure every affordability dollar pharmaceutical manufacturers spend on patients actually gets to them. Now for the first time in five years, we’re launching a new brand. We’re not changing anything about our company, our name or how we operate, but we want our presence to better reflect our values. RIS is the acronym for our core pillars—resilience, innovation, service. Those are the values we will continue to hold ourselves to as we help manufacturers overcome GTN blind spots through GTN Revenue Protection that strengthens patient affordability programs. Over the past 5 years, we’ve been able to save billions of dollars in revenue for the leading players in the pharma industry by catching leakage in real time, not months later when the damage has been done. The goal of our new brand is to show our commitment to a positive upward trajectory, not just for GTN savings, but increased patient access. As we step into our bright, newly branded future, we’re going to keep: → Rising to support our customers → Rising to meet the challenges presented to us → Rising to great heights as a company The brand may evolve. The logo may change again to reflect that evolution. But our mission—and the people who built it—won’t. https://risrx.com/

Patient disruption impacts millions of Americans every year—and most of the time, it’s due to cost. At RIS Rx, we believe that when a patient walks away from the pharmacy counter due to unexpected costs, it isn't just a revenue leakage problem—it’s a clinical failure. When life-saving therapy is interrupted, the manufacturer loses revenue, but the patient loses their path to health. Our CEO, Gerard Rivera, writes about this on Drug Channels here: https://lnkd.in/gpUBq2fi

RIS Rx was founded by pharmacists who've been at the counter with patients and in the boardroom with executives managing billion-dollar budgets. That vantage point has shaped a real-time solution that addresses the $90 billion leakage problem. This problem can feel abstract, until you realize what it means: 💸 Billions budgeted for affordability programs that never reach patients. 💸 Manufacturers losing profit they thought was protected. 💸 Retroactive audits that chase leaks months after the dollars are gone. In 2024, our clients saved $450M. In 2025, we’re forecasting $1B+. And every dollar protected means more patients staying on therapy. If you want to learn more about how we help with Gross-to-Net leakage, you can read more in our piece on Drug Channels:

$90 billion. That’s the scale of gross-to-net leakage in 2024 once copay leakage, 340B, and rebates are accounted for. Legacy approaches can’t keep up. By the time they find the problem, the dollars are gone. Here’s how RIS Rx changes that: ✅ Real-time monitoring ✅ Seamless integration with hubs + copay vendors ✅ A data vantage point no one else has ✅ Dynamic rules engine that adapts as accumulators and maximizers evolve Results: $450M saved in 2024. $1B forecast in 2025. Read the full piece on Drug Channels: asmbly.link/k83Cs6n

💸 $90 billion. That’s how much pharma loses to gross-to-net leakage each year. RIS Rx was built to stop it cold. 👉 $450M saved for clients in 2024 👉 $1B+ forecast for 2025 Every dollar to the patient. Every time. Read the full piece on Drug Channels:

We’re proud to announce a significant growth investment from Summit Partners to help fuel the next chapter of RIS Rx. Summit’s backing marks a major milestone in our mission to stop gross-to-net leakage and ensure that financial support reaches the patients who need it most. Their partnership will accelerate our platform innovation, expand our team, and deepen the impact we deliver for pharmaceutical manufacturers and their affordability programs. To our clients, partners, and advisors — thank you for your belief in us! And to the industry: we’re just getting started! #healthtech #pharma #patientaccess #gross2net #GTN #affordability #futureofcopay #growthjourney https://lnkd.in/gskJWCaC

We’re proud to announce a significant growth investment from Summit Partners to help fuel the next chapter of RIS Rx. Summit’s backing marks a major milestone in our mission to stop gross-to-net leakage and ensure that financial support reaches the patients who need it most. Their partnership will accelerate our platform innovation, expand our team, and deepen the impact we deliver for pharmaceutical manufacturers and their affordability programs. To our clients, partners, and advisors — thank you for your belief in us! And to the industry: we’re just getting started! #healthtech #pharma #patientaccess #gross2net #GTN #affordability #futureofcopay #growthjourney https://lnkd.in/gskJWCaC